Register entry
- Registered sites
- 0
- Active NDC listings
- 10
- Live patents
- 36
- Countries
- 0
Catalogue
Drug listings by form and route
1010 active NDC listings: 10 human prescription drug. By marketing category: NDA AUTHORIZED GENERIC 10.
| Dosage form | NDCs |
|---|---|
| tablet, orally disintegrating | 9 |
| suspension, extended release | 1 |
| Route | NDCs |
|---|---|
| oral | 10 |
| Labeller name on the listing | NDCs |
|---|---|
| neos therapeutics, lp | 10 |
Exclusivity
Patents and exclusivities
36| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 8709491 | ADZENYS ER, ADZENYS XR-ODTamphetamine | product | Jun 2032 |
| 9017731 | ADZENYS ER, ADZENYS XR-ODTamphetamine | product | Jun 2032 |
| 9072680 | COTEMPLA XR-ODTmethylphenidate | product | Jun 2032 |
| 9089496 | COTEMPLA XR-ODTmethylphenidate | product | Jun 2032 |
| 9265737 | ADZENYS ER, ADZENYS XR-ODTamphetamine | product | Jun 2032 |
| 9839619 | ADZENYS XR-ODTamphetamine | product | Jun 2032 |
| 11166947 | COTEMPLA XR-ODTmethylphenidate | use | Jan 2038 |
Catalogue
Marketed products
10| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| Amphetamine Extended-Release | Amphetamine Extended-Release | tablet, orally disintegrating, oral | 62542-005NDA AUTHORIZED GENERIC |
| Amphetamine Extended-Release | Amphetamine Extended-Release | tablet, orally disintegrating, oral | 62542-010NDA AUTHORIZED GENERIC |
| Amphetamine Extended-Release | Amphetamine Extended-Release | tablet, orally disintegrating, oral | 62542-015NDA AUTHORIZED GENERIC |
| Amphetamine Extended-Release | Amphetamine Extended-Release | tablet, orally disintegrating, oral | 62542-020NDA AUTHORIZED GENERIC |
| Amphetamine Extended-Release | Amphetamine Extended-Release | tablet, orally disintegrating, oral | 62542-025NDA AUTHORIZED GENERIC |
| Amphetamine Extended-Release | Amphetamine Extended-Release | tablet, orally disintegrating, oral | 62542-030NDA AUTHORIZED GENERIC |
| Carbinoxamine Maleate Extended-Release Oral Suspension | Carbinoxamine Maleate | suspension, extended release, oral | 62542-101NDA AUTHORIZED GENERIC |
| Methylphenidate Extended-Release | methylphenidate extended-release | tablet, orally disintegrating, oral | 62542-100NDA AUTHORIZED GENERIC |
| Methylphenidate Extended-Release | methylphenidate extended-release | tablet, orally disintegrating, oral | 62542-250NDA AUTHORIZED GENERIC |
| Methylphenidate Extended-Release | methylphenidate extended-release | tablet, orally disintegrating, oral | 62542-350NDA AUTHORIZED GENERIC |
Enquiry
Common questions
- Is Neos Therapeutics, LP FDA approved?
- Neos Therapeutics, LP holds no registered establishment of its own; 10 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Neos Therapeutics, LP make?
- 10 products are listed under Neos Therapeutics, LP in the openFDA NDC Directory, most often as tablet, orally disintegrating; suspension, extended release. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.